Descubra cómo hemos abordado los puntos débiles de la industria en ensayos clínicos anteriores. A continuación, encontrará nuestros estudios de casos más recientes.
VaxArt needed solutions for evaluating the safety and immunogenicity of its orally administered norovirus vaccine. Of particular importance was incorporating a way to quickly detect severe reactogenicity symptoms during the first week following vaccine administration.
A government agency is aiming to identify digital biomarkers of depressive and anxious feelings. The agency needed to capture both objective and subjective data for analysis.
ASD is a heterogeneous clinical condition, which makes it challenging to obtain clinical trial evidence for a targeted therapy. A biotech company aims to break down the one-size-fits-all approach to treating ASD and is seeking data to validate a more targeted strategy.
Medical device company, Mi-Helper, Inc., needed to find participants with a specific type of migraine. This required a long run-in period and mitigation to reduce the risk of drop-off before participants reached active treatment. In addition, Mi-Helper needed to ensure participants used the at-home device properly.
A biopharmaceutical company is seeking a Phase IV clinical trial to confirm the safety and efficacy of its ADHD therapeutic on a more real-world population. Phases I-III included narrow inclusion and exclusion criteria.